TEAD1 and gastric cancer: A multi-omics analysis of malignant ascitic fluid samples and tumor cell lines from 98 patients, stratified ascites-disseminated GC into two distinct molecular subtypes: “non-EMT” subtype displaying active super enhancers (SEs), and “EMT” subtype bearing TGF-β pathway activation and high expression of TEAD-1 [35].